Nkarta Appoints Manufacturing Technology Executive, Angela Thedinga, to Board of Directors
29 Marzo 2022 - 6:02AM
Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical
company developing engineered natural killer (NK) cell therapies to
treat cancer, announced today the appointment of Angela M.
Thedinga, MBA, MPH, to its Board of Directors.
“The speed of manufacturing innovation in cell and gene
therapies in recent years has accelerated significantly. Angela is
one of a handful of people who have been at the center of this
activity,” said Paul J. Hastings, President and CEO of Nkarta. “Her
expertise and insight in technical operations, supply chain and
commercial manufacturing will be instructive for Nkarta’s
operational strategy and the planned expansion of our in-house cell
therapy manufacturing capabilities. We welcome her to our Board and
look forward to her contributions.”
Angela Thedinga most recently served as Chief Technology Officer
of Adverum Biotechnologies, where she led the process development,
manufacturing and supply chain functions that supported the
development of ocular gene therapies. Before joining Adverum in
2019, she held executive roles in manufacturing and supply chain
management and strategy at AveXis, now Novartis Gene Therapies, to
deliver the first approved gene therapy for Spinal Muscular
Atrophy. Her earlier industry experience includes manufacturing
strategy roles in bioprocess engineering at Abbott Laboratories and
vaccine development at Novartis Vaccines and Diagnostics. She
earned an MBA and MS in Chemical Engineering from the Massachusetts
Institute of Technology (MIT), an MPH at the University of North
Carolina, Chapel Hill, and a BS in Chemical Engineering from
University of Wisconsin. She is a founding member of Chief, an
organization focused on connecting and supporting women executive
leaders.
“I’ve lived through the challenges of technology transfer,
supply chain and commercial-scale up of disruptive in vivo,
gene-engineered products,” said Angela Thedinga. “I am excited to
contribute my experience and perspective to the development and
delivery of off-the-shelf natural killer cell therapies. The
manufacturing capabilities of Nkarta are robust and impressive, and
I look forward to joining the Board and the Nkarta team as we
develop next generation cell therapies for cancer patients.”
About Nkarta Nkarta is a clinical-stage
biotechnology company advancing the development of allogeneic,
off-the-shelf natural killer (NK) cell immunotherapies for cancer
patients. By combining its cell expansion and cryopreservation
platform with proprietary cell engineering technologies and
CRISPR-based genome engineering capabilities, Nkarta is building a
pipeline of future cell therapies engineered for deep anti-tumor
activity and intended for broad access in the outpatient treatment
setting. For more information, please visit the company’s website
at www.nkartatx.com.
Cautionary Note on Forward-Looking
StatementsStatements contained in this press release
regarding matters that are not historical facts are
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, as amended. Words such as
"anticipates," "believes," "expects," "intends," “plans,”
“potential,” "projects,” “would,” and "future" or similar
expressions are intended to identify forward-looking statements.
Examples of these forward-looking statements include statements
concerning Nkarta’s expectations regarding any or all of the
following: Ms. Thedinga’s future contributions to Nkarta and the
benefits of her appointment to Nkarta’s Board; Nkarta’s ability to
build and advance a pipeline of NK cell therapies; expansion of
Nkarta’s in-house manufacturing capabilities; and the anti-tumor
activity and accessibility of Nkarta’s product candidates. Because
such statements are subject to risks and uncertainties, actual
results may differ materially from those expressed or implied by
such forward-looking statements. These risks and uncertainties
include, among others: Nkarta’s limited operating history and
historical losses; Nkarta’s lack of any products approved for sale
and its ability to achieve profitability; Nkarta’s ability to raise
additional funding to complete the development and any
commercialization of its product candidates; Nkarta’s dependence on
the success of its co-lead product candidates, NKX101 and NKX019;
that Nkarta may be delayed in initiating, enrolling or completing
any clinical trials; competition from third parties that are
developing products for similar uses; Nkarta’s ability to obtain,
maintain and protect its intellectual property; Nkarta’s dependence
on third parties in connection with manufacturing, clinical trials,
and pre-clinical studies; the complexity of the manufacturing
process for CAR NK cell therapies; and risks relating to the impact
on Nkarta’s business of the COVID-19 pandemic or similar public
health crises.
These and other risks are described more fully in Nkarta’s
filings with the Securities and Exchange Commission (“SEC”),
including the “Risk Factors” section of Nkarta’s Annual Report on
Form 10-K for the year ended December 31, 2021, filed with the SEC
on March 17, 2022, and Nkarta’s other documents subsequently filed
with or furnished to the SEC. All forward-looking statements
contained in this press release speak only as of the date on which
they were made. Except to the extent required by law, Nkarta
undertakes no obligation to update such statements to reflect
events that occur or circumstances that exist after the date on
which they were made.
Contacts:
Greg MannNkarta, Inc. gmann@nkartatx.com
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Sep 2024 a Oct 2024
Nkarta (NASDAQ:NKTX)
Gráfica de Acción Histórica
De Oct 2023 a Oct 2024